FI963779A0 - MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptidejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa - Google Patents

MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptidejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa

Info

Publication number
FI963779A0
FI963779A0 FI963779A FI963779A FI963779A0 FI 963779 A0 FI963779 A0 FI 963779A0 FI 963779 A FI963779 A FI 963779A FI 963779 A FI963779 A FI 963779A FI 963779 A0 FI963779 A0 FI 963779A0
Authority
FI
Finland
Prior art keywords
hla
scavenging
molecules
isolated peptides
peptides obtained
Prior art date
Application number
FI963779A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI963779A7 (fi
FI963779L (fi
Inventor
Alan Townsend
Judy Bastin
Thierry Boon-Falleur
Der Bruggen Pierre Van
Pierre Coulie
Thomas Gajewski
Cornelis J M Melief
M W Visseren
W M Kast
Original Assignee
Ludwig Inst Cancer Res
Cancellor Masters And Scholars
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/217,186 external-priority patent/US5585461A/en
Application filed by Ludwig Inst Cancer Res, Cancellor Masters And Scholars, Univ Leiden filed Critical Ludwig Inst Cancer Res
Publication of FI963779A7 publication Critical patent/FI963779A7/fi
Publication of FI963779A0 publication Critical patent/FI963779A0/fi
Publication of FI963779L publication Critical patent/FI963779L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI963779A 1994-03-24 1995-03-22 MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptidejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa FI963779L (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/217,186 US5585461A (en) 1994-03-24 1994-03-24 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US08/261,160 US5591430A (en) 1994-03-24 1994-06-17 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US08/290,381 US5851523A (en) 1994-03-24 1994-08-15 Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
PCT/US1995/003657 WO1995025740A1 (en) 1994-03-24 1995-03-22 Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules

Publications (3)

Publication Number Publication Date
FI963779A7 FI963779A7 (fi) 1996-09-23
FI963779A0 true FI963779A0 (fi) 1996-09-23
FI963779L FI963779L (fi) 1996-09-23

Family

ID=27396385

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963779A FI963779L (fi) 1994-03-24 1995-03-22 MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptidejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa

Country Status (16)

Country Link
US (1) US5851523A (de)
EP (2) EP0804483B1 (de)
JP (1) JP3536179B2 (de)
CN (1) CN1151170C (de)
AT (1) ATE198336T1 (de)
AU (1) AU698781B2 (de)
CA (1) CA2186004C (de)
DE (1) DE69519748T2 (de)
DK (1) DK0804483T3 (de)
ES (1) ES2154728T3 (de)
FI (1) FI963779L (de)
GR (1) GR3035636T3 (de)
NO (1) NO963919L (de)
NZ (1) NZ283587A (de)
PT (1) PT804483E (de)
WO (1) WO1995025740A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723832B1 (en) * 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
EP0785274B1 (de) * 1996-01-18 2000-09-27 Aventis Pharma Deutschland GmbH In kunstlisches Rekombinantes Substrat rAGG-1 und nativem Aggrecan zum Studium der proteolytischen Wirkung von 'Aggrecanase' in Zellkultursystemen
ATE377022T1 (de) * 1997-06-23 2007-11-15 Ludwig Inst Cancer Res Isolierte decapeptide, die an hla moleküle binden,sowie deren verwendung
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
US7090847B1 (en) * 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
EP1905832A3 (de) * 1999-09-09 2009-09-09 Schering Corporation Säuger Interleukin-12 P40 und Interleukin B30, Antikörper, Verwendungen in pharmazeutischen Zusammenstellungen
AU780163B2 (en) * 1999-09-09 2005-03-03 Merck Sharp & Dohme Corp. Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
CN1402782A (zh) * 1999-10-19 2003-03-12 路德维哥癌症研究院 Mage－a12抗原肽及其应用
US6897288B1 (en) 1999-10-19 2005-05-24 Ludwig Institute For Cancer Research Mage-A12 antigenic peptides and uses thereof
DK1282702T3 (da) 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
ES2290449T3 (es) 2002-04-09 2008-02-16 Sanofi Pasteur Limited Acido nucleico de cea modificado y vectores de expresion.
EP1556082A1 (de) * 2002-10-22 2005-07-27 Aventis Pasteur Limited Impfstoffe gegen krebs mit hochdosierten zytokinen als adjuvans
CA2550583C (en) * 2003-10-08 2013-01-15 Sanofi Pasteur, Inc. Modified cea /b7 vector
KR20100061480A (ko) * 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 치료제로서의 글루카곤（１－２９） 단독 또는 뉴로펩티드 ｗ３０과의 배합물의 용도
CN106117334B (zh) * 2016-06-24 2020-02-11 秦皇岛未名健康城开发有限公司 一种肿瘤抗原mage3的ctl识别表位肽及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
US5519117A (en) * 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
BR9406652A (pt) * 1993-03-05 1996-09-10 Cytel Corp Composição

Also Published As

Publication number Publication date
DK0804483T3 (da) 2001-02-12
EP0960622A2 (de) 1999-12-01
JP3536179B2 (ja) 2004-06-07
ATE198336T1 (de) 2001-01-15
ES2154728T3 (es) 2001-04-16
AU698781B2 (en) 1998-11-05
CN1151170C (zh) 2004-05-26
NO963919D0 (no) 1996-09-19
AU2192895A (en) 1995-10-09
FI963779A7 (fi) 1996-09-23
WO1995025740A1 (en) 1995-09-28
CA2186004A1 (en) 1995-09-28
PT804483E (pt) 2001-06-29
DE69519748D1 (de) 2001-02-01
CA2186004C (en) 2008-09-23
CN1150805A (zh) 1997-05-28
NO963919L (no) 1996-11-20
EP0804483B1 (de) 2000-12-27
NZ283587A (en) 1998-04-27
JPH10504518A (ja) 1998-05-06
GR3035636T3 (en) 2001-06-29
FI963779L (fi) 1996-09-23
EP0960622A3 (de) 1999-12-22
US5851523A (en) 1998-12-22
EP0804483A4 (de) 1998-05-20
DE69519748T2 (de) 2001-10-18
EP0804483A1 (de) 1997-11-05

Similar Documents

Publication Publication Date Title
FI963779A0 (fi) MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptidejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa
ES2277362T5 (es) Antígenos y vacunas de streptococcus pneumoniae
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
ES2075196T3 (es) Metodo para el uso y la sintesis de peptidos.
BR9811039A (pt) Citocina de mamìferos: interleucina-b30 e reagentes relacionados
DE69738749D1 (de) Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
FI961251A0 (fi) Ihmisten metabotrooppiset glutamaattireseptorialatyypit(HMR4, HMR6, HMR7)ja niihin liittyvät DNA-yhdisteet
DE69324359D1 (de) Verbessertes verfahren zur herstellung von endotoxinbindungsproteinen
ES2129622T3 (es) Receptores para interleuquina-10 de mamifero.
EA199900869A1 (ru) Цитокин-подобный фактор 7 млекопитающих
DE69738811D1 (de) Oberflächenantigene aus Säugern
IL111479A0 (en) Chimeric proteins comprising borrelia polypetides and uses therefor
DK0894143T4 (da) VMP-lignende sekvenser af patogenisk Borrelia
IL105769A0 (en) Immobilized buffered gels and membranes of hydroxy group-containing polymers
WO2000042188A3 (en) Interleukin-17 related mammalian cytokines. polynucleotides encoding them. uses
SE9602496D0 (sv) Method and means for producing a fibrinogen binding protein and its use in biotechnology
DE69333382D1 (de) Hyaluronan rezeptor (rezeptor durch hyaluronan verurzachte bewelichkeit) und hyaluronan bindende peptide
EP0687911A3 (de) Verfahren zumm Assay von Endotoxin-Konzentration
CY1108288T1 (el) Αντισωματα για το αντιγονο κυτταρων langerhans θηλαστικων και χρησεις τους
PT97355A (pt) Processo para a preparacao de polipeptidos recombinantes contendo uma sequencia de aminoacidos de uma proteina de celulas
EP0990703A4 (de) Neues polypeptid, dafür kodierende dna und deren verwendungen
DE69728897D1 (de) Saeugetierchemokine
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
AR022150A1 (es) Acidos nucleicos derivados de monocitos y composiciones y metodos relacionados
AU3931599A (en) Basb019 proteins and genes from (moraxella catarrhalis), antigens, antibodies, and uses